Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 51377 4s 0?
Displaying drugs 526 - 550 of 1462 in total
Experimental
Matched Synonyms: … PHC-C 18:0/18:0 ... phytosphingosine-2-hydroxy-18:0
Ceramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3 consists of a phytosphingosine backbone N-acylated with a saturated fatty acid (stearic acid) . It is widely used as a...
Experimental
Matched Synonyms: … Cer(t18:0/18:1n-9) …
Caprylic acid is an eight-carbon chain fatty acid, also known systematically as octanoic acid. It is found naturally in coconuts and breast milk. It is an oily liquid with a slightly unpleasant rancid-like smell that is minimally soluble in water.
Investigational
Matched Synonyms: … C8:0
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
Investigational
Matched Description: … PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47) …
PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.
Investigational
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
Investigational
O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms.
Investigational
Ro4929097 has been used in trials studying the treatment of Sarcoma, LYMPHOMA, Neoplasms, Wilm's Tumor, and OSTEOSARCOMA, among others.
Investigational
MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with all stages of prostate, pancreatic and bladder cancers.
Investigational
VS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).
Investigational
AVX-470 is an anti-tumor necrosis factor (TNF) polyclonal antibody (bovine).
Investigational
PF-00477736 has been used in trials studying the treatment of Neoplasms.
Investigational
Experimental
Investigational
Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome).
Investigational
ZSTK474 has been used in trials studying the treatment of Neoplasms.
Investigational
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Investigational
FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.
Investigational
Investigational
Investigational
Investigational
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Displaying drugs 526 - 550 of 1462 in total